In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy
Year: 2026
Type: article
Abstract: Oncolytic adenoviruses (OVs) can directly eliminate cancer cells and subsequently activate immune responses, exhibiting potent antitumor therapeutics. However, it was observed that the immune cells can also be lysed during viral treatment, evidently dampening the OVs-mediated antitumor immune response. In this study, we develop a microneedle (MN)-based in situ tumor cell-derived extracellular nanovesicle (TDEV)-cloaked OVs platform to enhance cancer immunotherapy and reduce immune cell exhaustion. In this platform, tumor cells pre-infected with OVs are loaded into the upper reservoir of the MN device. Following the transdermal administration, the hollow MN would constantly facilitate the transport of in situ the generated TDEV-encapsulating OVs into the tumor site for sustained delivery of OVs, which could subsequently infect cancer cells selectively rather than immune cells. Enhanced antigens triggered by improved intratumoral OVs killing can be presented by non-exhausted dendritic cells, further evoking significant immunotherapeutic effects in both TC-1-hCD46 xenograft tumor-bearing mice and postoperative tumor recurrence mice models.
DOI: 10.1002/jev2.70222
Authors: Tianye Wang, Sheng Zhao, Zao Ji, Zhonggui He, Zhenguo Cheng, Zhen Gu, Yuqi Zhang, Jin Sun, Funan Liu, Mengchi Sun
Institutions: Dalian Medical University, First Hospital of China Medical University, First Affiliated Hospital of Dalian Medical University, China Medical University, Zhejiang University, Shenyang Pharmaceutical University, Zhengzhou University, Sir Run Run Shaw Hospital, Second Affiliated Hospital of Zhejiang University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,410
OpenAlex ID: W7119148027